Development of the "Dissolution" Test Method for Tablets of Sodium 4,4'-(propanediamido)dibenzoate with Sustained Release

Introduction. Non-alcoholic fatty liver disease is one of the most common chronic diseases of this parenchymal organ among the adult population. The search and creation of supporting drugs is an urgent task of modern pharmacy. The malonic acid derivative, sodium 4,4'-(propanediamido) dibenzoate...

Full description

Saved in:
Bibliographic Details
Main Authors: E. V. Flisyuk, Ju. M. Kotsur, I. A. Narkevich, I. E. Smekhova, D. Yu. Ivkin
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2021-12-01
Series:Разработка и регистрация лекарственных средств
Subjects:
Online Access:https://www.pharmjournal.ru/jour/article/view/1113
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849395333426053120
author E. V. Flisyuk
Ju. M. Kotsur
I. A. Narkevich
I. E. Smekhova
D. Yu. Ivkin
author_facet E. V. Flisyuk
Ju. M. Kotsur
I. A. Narkevich
I. E. Smekhova
D. Yu. Ivkin
author_sort E. V. Flisyuk
collection DOAJ
description Introduction. Non-alcoholic fatty liver disease is one of the most common chronic diseases of this parenchymal organ among the adult population. The search and creation of supporting drugs is an urgent task of modern pharmacy. The malonic acid derivative, sodium 4,4'-(propanediamido) dibenzoate, synthesized by the employees of the Department of Organic Chemistry of the SPСPU, has antisteatous activity, is a potential agent for the treatment of liver diseases. Sustained release tablets were prepared based on sodium 4,4'-(propanediamido)dibenzoate. An integral part of the pharmaceutical development of a medicinal product is the development of a method for conducting the Dissolution test and the selection of optimal conditions, which became the purpose of this study.Aim. To develop the "Dissolution" test method for the sustained-release tablets based on sodium 4,4'-(propanediamido)dibenzoate.Materials and methods. The objects of research are the active pharmaceutical ingredient sodium 4,4'-(propanediamido)dibenzoate, as well as sustained-release tablets based on this substance. Equilibrium biopharmaceutical solubility was determined by UV-spectrophotometry. To establish the conditions for the "Dissolution" test, an ERWEKA DT-620 dissolution tester (ERWEKA GmbH, Germany) was used.Results and discussion. The suitability of the UV-spectrophotometry method for the quantitative determination of sodium 4,4'-(propanediamido) dibenzoate in solutions was determined. The established high biopharmaceutical solubility of sodium 4,4'-(propanediamido)dibenzoate in a buffer solution with a pH of 6,8, as well as in a 0,01 M solution of hydrochloric acid with a pH of 2,6, determined the choice of these media for the "Dissolution" test of the dosage form. The apparatus "Rotating basket" (rotation speed of 100 rpm in a dissolution medium with a volume of 1000 ml) was reasonably chosen for the test on the basis of the obtained linear dependence of the rate of release of the substance on time, as well as the best test results by the end of the experiment.Conclusion. A study of the biopharmaceutical properties of the original substance with antisteatous activity has been carried out. High biopharmaceutical solubility was established in media with pH 2,6 and pH 6,8. The conditions of the "Dissolution" test for sustained-release tablets based on the original sodium 4,4'-(propanediamido)dibenzoate were experimentally substantiated.
format Article
id doaj-art-78cd1301863443ce8a5c8282b657690f
institution Kabale University
issn 2305-2066
2658-5049
language Russian
publishDate 2021-12-01
publisher LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
record_format Article
series Разработка и регистрация лекарственных средств
spelling doaj-art-78cd1301863443ce8a5c8282b657690f2025-08-20T03:39:40ZrusLLC Center of Pharmaceutical Analytics (LLC «CPHA»)Разработка и регистрация лекарственных средств2305-20662658-50492021-12-0110414615410.33380/2305-2066-2021-10-4(1)-146-154920Development of the "Dissolution" Test Method for Tablets of Sodium 4,4'-(propanediamido)dibenzoate with Sustained ReleaseE. V. Flisyuk0Ju. M. Kotsur1I. A. Narkevich2I. E. Smekhova3D. Yu. Ivkin4Saint-Petersburg State Chemical-Pharmaceutical UniversitySaint-Petersburg State Chemical-Pharmaceutical UniversitySaint-Petersburg State Chemical-Pharmaceutical UniversitySaint-Petersburg State Chemical-Pharmaceutical UniversitySaint-Petersburg State Chemical-Pharmaceutical UniversityIntroduction. Non-alcoholic fatty liver disease is one of the most common chronic diseases of this parenchymal organ among the adult population. The search and creation of supporting drugs is an urgent task of modern pharmacy. The malonic acid derivative, sodium 4,4'-(propanediamido) dibenzoate, synthesized by the employees of the Department of Organic Chemistry of the SPСPU, has antisteatous activity, is a potential agent for the treatment of liver diseases. Sustained release tablets were prepared based on sodium 4,4'-(propanediamido)dibenzoate. An integral part of the pharmaceutical development of a medicinal product is the development of a method for conducting the Dissolution test and the selection of optimal conditions, which became the purpose of this study.Aim. To develop the "Dissolution" test method for the sustained-release tablets based on sodium 4,4'-(propanediamido)dibenzoate.Materials and methods. The objects of research are the active pharmaceutical ingredient sodium 4,4'-(propanediamido)dibenzoate, as well as sustained-release tablets based on this substance. Equilibrium biopharmaceutical solubility was determined by UV-spectrophotometry. To establish the conditions for the "Dissolution" test, an ERWEKA DT-620 dissolution tester (ERWEKA GmbH, Germany) was used.Results and discussion. The suitability of the UV-spectrophotometry method for the quantitative determination of sodium 4,4'-(propanediamido) dibenzoate in solutions was determined. The established high biopharmaceutical solubility of sodium 4,4'-(propanediamido)dibenzoate in a buffer solution with a pH of 6,8, as well as in a 0,01 M solution of hydrochloric acid with a pH of 2,6, determined the choice of these media for the "Dissolution" test of the dosage form. The apparatus "Rotating basket" (rotation speed of 100 rpm in a dissolution medium with a volume of 1000 ml) was reasonably chosen for the test on the basis of the obtained linear dependence of the rate of release of the substance on time, as well as the best test results by the end of the experiment.Conclusion. A study of the biopharmaceutical properties of the original substance with antisteatous activity has been carried out. High biopharmaceutical solubility was established in media with pH 2,6 and pH 6,8. The conditions of the "Dissolution" test for sustained-release tablets based on the original sodium 4,4'-(propanediamido)dibenzoate were experimentally substantiated.https://www.pharmjournal.ru/jour/article/view/1113dissolution testreleasesustained-release tabletsmalonic acid derivativebiopharmaceutical solubility
spellingShingle E. V. Flisyuk
Ju. M. Kotsur
I. A. Narkevich
I. E. Smekhova
D. Yu. Ivkin
Development of the "Dissolution" Test Method for Tablets of Sodium 4,4'-(propanediamido)dibenzoate with Sustained Release
Разработка и регистрация лекарственных средств
dissolution test
release
sustained-release tablets
malonic acid derivative
biopharmaceutical solubility
title Development of the "Dissolution" Test Method for Tablets of Sodium 4,4'-(propanediamido)dibenzoate with Sustained Release
title_full Development of the "Dissolution" Test Method for Tablets of Sodium 4,4'-(propanediamido)dibenzoate with Sustained Release
title_fullStr Development of the "Dissolution" Test Method for Tablets of Sodium 4,4'-(propanediamido)dibenzoate with Sustained Release
title_full_unstemmed Development of the "Dissolution" Test Method for Tablets of Sodium 4,4'-(propanediamido)dibenzoate with Sustained Release
title_short Development of the "Dissolution" Test Method for Tablets of Sodium 4,4'-(propanediamido)dibenzoate with Sustained Release
title_sort development of the dissolution test method for tablets of sodium 4 4 propanediamido dibenzoate with sustained release
topic dissolution test
release
sustained-release tablets
malonic acid derivative
biopharmaceutical solubility
url https://www.pharmjournal.ru/jour/article/view/1113
work_keys_str_mv AT evflisyuk developmentofthedissolutiontestmethodfortabletsofsodium44propanediamidodibenzoatewithsustainedrelease
AT jumkotsur developmentofthedissolutiontestmethodfortabletsofsodium44propanediamidodibenzoatewithsustainedrelease
AT ianarkevich developmentofthedissolutiontestmethodfortabletsofsodium44propanediamidodibenzoatewithsustainedrelease
AT iesmekhova developmentofthedissolutiontestmethodfortabletsofsodium44propanediamidodibenzoatewithsustainedrelease
AT dyuivkin developmentofthedissolutiontestmethodfortabletsofsodium44propanediamidodibenzoatewithsustainedrelease